HBIO
Price
$3.37
Change
-$0.07 (-2.03%)
Updated
May 17, 6:59 PM EST
80 days until earnings call
THMO
Price
$0.58
Change
+$0.06 (+11.54%)
Updated
May 17, 6:59 PM EST
Ad is loading...

HBIO vs THMO

Header iconHBIO vs THMO Comparison
Open Charts HBIO vs THMOBanner chart's image
Harvard Bioscience
Price$3.37
Change-$0.07 (-2.03%)
Volume$34.53K
CapitalizationN/A
ThermoGenesis Holdings
Price$0.58
Change+$0.06 (+11.54%)
Volume$52.71K
CapitalizationN/A
View a ticker or compare two or three
HBIO vs THMO Comparison Chart

Loading...

HBIODaily Signal changed days agoGain/Loss if shorted
 
Show more...
THMODaily Signal changed days agoGain/Loss if shorted
 
Show more...
VS
HBIO vs. THMO commentary
May 19, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is HBIO is a Hold and THMO is a Hold.

COMPARISON
Comparison
May 19, 2024
Stock price -- (HBIO: $3.37 vs. THMO: $0.59)
Brand notoriety: HBIO and THMO are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: HBIO: 55% vs. THMO: 269%
Market capitalization -- HBIO: $184.01M vs. THMO: $2.24M
HBIO [@Medical Specialties] is valued at $184.01M. THMO’s [@Medical Specialties] market capitalization is $2.24M. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $7.49B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

HBIO’s FA Score shows that 1 FA rating(s) are green whileTHMO’s FA Score has 0 green FA rating(s).

  • HBIO’s FA Score: 1 green, 4 red.
  • THMO’s FA Score: 0 green, 5 red.
According to our system of comparison, HBIO is a better buy in the long-term than THMO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

HBIO’s TA Score shows that 4 TA indicator(s) are bullish while THMO’s TA Score has 4 bullish TA indicator(s).

  • HBIO’s TA Score: 4 bullish, 5 bearish.
  • THMO’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, both HBIO and THMO are a bad buy in the short-term.

Price Growth

HBIO (@Medical Specialties) experienced а -4.53% price change this week, while THMO (@Medical Specialties) price change was -12.40% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was +2.34%. For the same industry, the average monthly price growth was +4.51%, and the average quarterly price growth was +16.96%.

Reported Earning Dates

HBIO is expected to report earnings on Aug 07, 2024.

THMO is expected to report earnings on Mar 27, 2023.

Industries' Descriptions

@Medical Specialties (+2.34% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
A.I.dvisor published
a Summary for HBIO with price predictions.
OPEN
A.I.dvisor published
a Summary for THMO with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
HBIO($184M) has a higher market cap than THMO($2.24M). THMO YTD gains are higher at: -2.346 vs. HBIO (-37.009). HBIO has higher annual earnings (EBITDA): 8.03M vs. THMO (-5.08M). HBIO has more cash in the bank: 4.28M vs. THMO (4.02M). THMO has less debt than HBIO: THMO (8.34M) vs HBIO (42.8M). HBIO has higher revenues than THMO: HBIO (112M) vs THMO (9.72M).
HBIOTHMOHBIO / THMO
Capitalization184M2.24M8,203%
EBITDA8.03M-5.08M-158%
Gain YTD-37.009-2.3461,577%
P/E RatioN/A1.86-
Revenue112M9.72M1,153%
Total Cash4.28M4.02M107%
Total Debt42.8M8.34M513%
FUNDAMENTALS RATINGS
HBIO vs THMO: Fundamental Ratings
HBIO
THMO
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
99
Overvalued
66
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
91100
PRICE GROWTH RATING
1..100
8791
P/E GROWTH RATING
1..100
299
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

THMO's Valuation (66) in the null industry is somewhat better than the same rating for HBIO (99) in the Biotechnology industry. This means that THMO’s stock grew somewhat faster than HBIO’s over the last 12 months.

THMO's Profit vs Risk Rating (100) in the null industry is in the same range as HBIO (100) in the Biotechnology industry. This means that THMO’s stock grew similarly to HBIO’s over the last 12 months.

HBIO's SMR Rating (91) in the Biotechnology industry is in the same range as THMO (100) in the null industry. This means that HBIO’s stock grew similarly to THMO’s over the last 12 months.

HBIO's Price Growth Rating (87) in the Biotechnology industry is in the same range as THMO (91) in the null industry. This means that HBIO’s stock grew similarly to THMO’s over the last 12 months.

HBIO's P/E Growth Rating (2) in the Biotechnology industry is significantly better than the same rating for THMO (99) in the null industry. This means that HBIO’s stock grew significantly faster than THMO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
HBIOTHMO
RSI
ODDS (%)
Bullish Trend 3 days ago
76%
Bullish Trend 3 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
75%
Bullish Trend 3 days ago
90%
Momentum
ODDS (%)
Bearish Trend 3 days ago
81%
Bearish Trend 3 days ago
90%
MACD
ODDS (%)
Bearish Trend 3 days ago
79%
Bearish Trend 3 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
80%
Bearish Trend 3 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
79%
Bearish Trend 3 days ago
90%
Advances
ODDS (%)
Bullish Trend 5 days ago
77%
Bullish Trend 6 days ago
85%
Declines
ODDS (%)
Bearish Trend 3 days ago
79%
Bearish Trend 4 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
90%
Bullish Trend 3 days ago
88%
Aroon
ODDS (%)
Bearish Trend 3 days ago
77%
N/A
View a ticker or compare two or three
Ad is loading...
HBIODaily Signal changed days agoGain/Loss if shorted
 
Show more...
THMODaily Signal changed days agoGain/Loss if shorted
 
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
RELI0.310.02
+7.86%
Reliance Global Group
PSN76.51-0.04
-0.05%
Parsons Corp
CLDT9.02-0.04
-0.44%
Chatham Lodging Trust
AGIO34.34-0.66
-1.89%
Agios Pharmaceuticals
PFIE1.38-0.04
-2.82%
Profire Energy

HBIO and

Correlation & Price change

A.I.dvisor indicates that over the last year, HBIO has been loosely correlated with FLGT. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if HBIO jumps, then FLGT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HBIO
1D Price
Change %
HBIO100%
-2.03%
FLGT - HBIO
38%
Loosely correlated
-1.73%
CTKB - HBIO
32%
Poorly correlated
-1.29%
ATRC - HBIO
31%
Poorly correlated
+2.25%
BFLY - HBIO
31%
Poorly correlated
+1.98%
KIDS - HBIO
30%
Poorly correlated
+0.72%
More

THMO and

Correlation & Price change

A.I.dvisor tells us that THMO and CORBF have been poorly correlated (+26% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that THMO and CORBF's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To THMO
1D Price
Change %
THMO100%
+12.74%
CORBF - THMO
26%
Poorly correlated
-1.60%
HBIO - THMO
25%
Poorly correlated
-2.03%
APDN - THMO
25%
Poorly correlated
-8.73%
GENE - THMO
23%
Poorly correlated
-0.44%
BFLY - THMO
23%
Poorly correlated
+1.98%
More